VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research note released on Thursday. The firm issued a sell rating on the stock.

Separately, Benchmark restated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Stock Up 1.6 %

Shares of NYSE:VNRX opened at $0.70 on Thursday. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.23. The stock has a market cap of $64.57 million, a price-to-earnings ratio of -1.94 and a beta of 1.10. The business has a 50-day moving average price of $0.69 and a 200-day moving average price of $0.68.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC increased its stake in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.